Previous 10 | Next 10 |
ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announ...
Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 pre...
ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces th...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here . Source: Chad McDermott...
Gainers: ReWalk Robotics (NASDAQ:RWLK) +37%, Ontrak (NASDAQ:OTRK) +35%, Alzamend Neuro (NASDAQ:ALZN) +32%, Chinook Therapeutics (NASDAQ:KDNY) +23%, Alimera Sciences (NASDAQ:ALIM) +22%. Losers: Deciphera Pharmaceuticals (NASDAQ:DCPH) -74%, Cali...
Image source: The Motley Fool. Alimera Sciences, inc (NASDAQ: ALIM) Q3 2021 Earnings Call Oct 28, 2021 , 9:00 a.m. ET Operator Continue reading For further details see: Alimera Sciences, inc (ALIM) Q3 2021 Earnings Call Transcript
Alimera Sciences, Inc. (ALIM) Q3 2021 Earnings Conference Call October 28, 2021, 09:00 ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President, CEO & Director Philip Jones - CFO Conference Call Participants Alexander Nowak - Craig-Hallum Yi Chen - H.C. Wainwright &...
Alimera Sciences (NASDAQ:ALIM): Q3 GAAP EPS of -$0.60 misses by $0.07. Revenue of $12.15M (-2.6% Y/Y) misses by $0.22M. Press Release For further details see: Alimera Sciences EPS misses by $0.07, misses on revenue
Consolidated Net Revenue of $12.2 Million Down 2% vs. Third Quarter of 2020 and Up 14% vs. Second Quarter of 2021 U.S. End User Demand up 15% vs. Third Quarter of 2020 and Second Quarter of 2021 ATLANTA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences,...
AB, ABEV, ABMD, ADS, AEP, AGCO, ALDX, ALIM, ALNY, AMT, AOS, ARGX, ASX, OTCPK:ATGFF, ATI, AVNT, BAX, BC, OTCQX:BDRBF, BPMC, BTU, BUD, CARR, CAT, CBRE, CFR, CG, CHKP, CMCSA, CMS, CNSL, CNX, COHU, COOP, COR, CPG, CRS, CVEO, CWT, CX, OTCPK:DASTY, DBD, DQ, OTCPK:EADSF, EXP, FLWS, GNCA, GPI, GTX, G...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Perficient, Inc. (NASDAQ:PRFT)'s sal...
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alimera Sciences, Inc. (NASDAQ:ALIM)'...